Abstract

In March 2021, Novartis announced a positive result for both primary endpoints of the randomized phase III VISION study on 177Lu-PSMA-617 radioligand therapy (RLT). 177Lu-PSMA-617 RLT and the best standard of care improved both overall and radiographic progression-free survival when compared with

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call